Swiss pharmaceutical company Roche Holdings announced that its experimental weight loss drug CT-388 showed promising results in early-stage clinical trials. The company said that during the 24-week trial, patients lost 18.8% of their weight compared to the placebo control group by injecting CT-388 once a week. Recently, Novo Nordisk launched Wegovy and Eli Lilly launched Zepbound.
减重18.8%！罗氏：减肥药CT-388效果喜人
18.8% weight loss! Roche: The results of the diet pill CT-388 are impressive
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.